X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will enable COUR to advance multiple, wholly owned product candidates that leverage the company’s immune tolerance platform, including Phase 2a proof-of-concept clinical studies evaluating CNP-106 in Myasthenia Gravis and CNP-103 in Type 1 Diabetes.
Lead Product(s): CNP-106
Therapeutic Area: Immunology Product Name: CNP-106
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Umira Ventures
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 30, 2024
Details:
CNP-106 has the potential to halt and reverse myasthenia gravis (MG) by reprogramming T cells to promote immune tolerance through T regulatory cells.
Lead Product(s): CNP-106
Therapeutic Area: Immunology Product Name: CNP-106
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
CNP-104 uses COUR's proprietary nanoparticle platform (CNP), a novel system which combines disease specific pathogenic antigens with state-of-the-art pharmaceutical nanoparticles that mimic normal removal of dead or dying liver cells from the body.
Lead Product(s): Nanoparticle Encapsulating PDC-E2
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CNP-104
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
This agreement gives Ironwood an option to acquire an exclusive license to develop and commercialize, in the U.S., COUR’s investigational therapy CNP-104 (the “License”), which if successful, could transform the treatment of Primary Biliary Cholangitis.
Lead Product(s): Nanoparticle Encapsulating PDC-E2
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CNP-104
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Ironwood Pharmaceuticals
Deal Size: $495.0 million Upfront Cash: $20.0 million
Deal Type: Acquisition November 04, 2021
Details:
CNP-104, a biodegradable nanoparticle encapsulating PDC-E2 to address autoimmune causes of Primary Biliary Cholangitis (PBC).
Lead Product(s): Nanoparticle Encapsulating PDC-E2
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CNP-104
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
CNP-201 is biodegradable nanoparticle encapsulating purified peanut protein extract and administered through intravenous infusion. First-of-its-kind study will evaluate safety and efficacy of CNP-201 in proof-of-concept study in people who are allergic to peanuts.
Lead Product(s): CNP-201
Therapeutic Area: Immunology Product Name: CNP-201
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
